Vardenafil Treatment for Erectile Dysfunction

Annals of Pharmacotherapy

Volumn 38, Issue 1, 2004, Pages 77-85

  Crowe, Susan M ^a,b   Streetman, Daniel S ^a,b,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UHB2D301/Box 0008 ^*  (United States)

Author keywords

Erectile dysfunction; Phosphodiesterase; Vardenafil

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; CIMETIDINE; CYTOCHROME P450 3A4; DIGOXIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; NIFEDIPINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PLACEBO; SILDENAFIL; VARDENAFIL;

ADULT; AGED; AREA UNDER THE CURVE; BLOOD PRESSURE; DIABETES MELLITUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMPOTENCE; MALE; MEDLINE; METABOLISM; NORMAL HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATECTOMY; REVIEW; RHINITIS; ST SEGMENT DEPRESSION; TACHYCARDIA; TIME; VISUAL IMPAIRMENT;

EID: 0347623332     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D019     Document Type: Review

References (43)

1. NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA 1993;270:83-90.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
3. Schein M, Zyzanski SJ, Levine S, Medalie JH, Dickman RL, Alemagno MA. The frequency of sexual problems among family practice patients. Fam Pract Res J 1988;7:122-34.
4. Slag MF, Morley JE, Elson MK, Trence DL, Nelson CJ, Nelson AE, et al. Impotence in medical clinic outpatients. JAMA 1983;249:1736-40.
5. Diokno AC, Brown MB, Herzog AR. Sexual function in the elderly. Arch Intern Med 1990;150:197-200.
6. Monga M, Bettencourt R, Barrett-Connor E. Community-based study of erectile dysfunction and sildenafil use: the Rancho Bernardo study. Urology 2002;59:753-7.
7. Population by age, sex, race, and Hispanic or Latino origin for the United States: 2000 (PHC-T-9). October 31, 2001. United States Census Bureau. www.census.gov/population/www/cen2000/phc-t9.html (accessed 2002 Dec 20).
8. Lue TF. Erectile dysfunction. N Engl J Med 2000:342:1802-13.
9. Niederberger C, Lonsdale J. Erectile dysfunction-patient characteristics and attitudes based on a large-scale male health study conducted in US. Europe, Mexico and Brazil (abstract). J Urol 2002;167(suppl):148.
10. Derby CA, Barbour MM, Hume AL, McKinlay JB. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001;21:676-83.
11. Pfizer Annual Report 2001. Pfizer Incorporated. www.pfizer.com/are/investors_reports/index.cfm (accessed 2002 Dec 20).
12. Top 200 most prescribed drugs. Mosby's Drug Consult. www. mosbysdrugconsult.com/DrugConsult/Top_200/ (accessed 2002 Dec 20).
13. Haning H, Niewohner U, Schenke T, Es-Sayed M, Schmidt G, Lampe T, et al. Imidazo[5, 1-f][1,2,4]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. Bioorg Med Chem Lett 2002;12:865-8.
14. Terrett NK, Bell AS, Brown D, Ellis P. Sildenafil (Viagra), a potent and selective inhibitor of type 5 CGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett 1996;6:1819-24.
15. Manecke RG, Mulhall JP. Medical treatment of erectile dysfunction. Ann Med 1999;31:388-98.
16. Kim NN, Huang Y, Goldstein I, Bischoff E, Traish AM. Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci 2001;69:2249-56.
17. Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE 5 inhibitor vardenafil. Int J Impot Res 2001;13:282-90.
18. Bischoff E, Schneider K. A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. Int J Impot Res 2001;13:230-5.
19. Bischoff E, Niewoehner U, Haning H, Es Sayed M, Schenke T, Schlemmer KH. The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model. J Urol 2001:165:1316-8.
20. Choi S, O'Connell L, Min K, Kim NN, Munarriz R, Goldstein I, et al. Efficacy of vardenafil and sildenafil in facilitating penile erection in an animal model. J Androl 2002;23:332-7.
21. Klotz T, Sachse R, Heidrich A, Jockenhovel F, Rohde G, Wensing G, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001;19:32-9.
22. Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G, et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001;40:181-90.
23. Rohde G, Wensing G, Sachse R. The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, are not affected by the antacid Maalox 70 (abstract). Pharmacotherapy 2001;21:1254.
24. Rohde G, Wensing G, Unger S, Sachse R. The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, is minimally affected by coadministration with cimetidine or ranitidine (abstract). Pharmacotherapy 2001;21:1254.
25. Bauer RJ, Rohde G, Wensing G. The interaction of alcohol with vardenafil, a potent and highly selective phosphodiesterase type 5 inhibitor (abstract). Pharmacotherapy 2002:22:418.
26. Data on file. West Haven, CT: Bayer Pharmaceuticals.
27. Rajagopalan P, Mazzu A, Xia CH, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, and oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003;43:260-7.
28. Klotz T, Bauer RJ, Rohde G. Effect of renal impairment on the singledose pharmacokinetics of vardenafil 20 mg, a selective PDE5 inhibitor, for the treatment of erectile dysfunction (abstract). Pharmacotherapy 2002;22:418.
29. Steidle CP, Feldman RA, Lettieri J, Agarwal V, Segerson T, Hollister A. Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data of efficacy and safety in elderly patients with erectile dysfunction (abstract). J Am Geriatr Soc 2001;49:S103.
30. Sachse R, Rohde G, Stark S, Klotz T. Safety, tolerability and pharmacokinetics of BAY 38-9456 in patients with erectile dysfunction (abstract). J Urol 2000;163(suppl):204.
31. Rohde G, Bauer RJ, Unger S, Ahr G, Wensing G, Kuhlmann J. Vardenafil, a new selective PDE5 inhibitor, produces no interaction with digoxin (abstract). Pharmacotherapy 2001;21:1254.
32. Rohde G, Jordan PJ. Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy (abstract). Pharmacotherapy 2002;22:418.
33. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001;13:192-9.
34. Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002;23:763-71.
35. Goldstein I, Young J, Fischer J, Mollen M, Chu F, Shapiro J, et al. Vardenafil, a new highly selective PDE5 inhibitor, improves erectile dysfunction in patients with diabetes mellitus (abstract). Diabetes 2001;50(suppl 2):A114.
36. Goldstein I, Young J, Segerson T, Thibonnier M. Long-term efficacy and safety of vardenafil in diabetic men with erectile dysfunction. Diabetes 2002;51(suppl 2):A98.
37. Brock G, Padma-Nathan H, Seger M. Efficacy and tolerability of vardenafil in males with erectile dysfunction following radical prostatectomy. Presented at: XVII Annual Congress of the European Association of Urology, Birmingham, United Kingdom. February 23-26, 2002.
38. Padma-Nathan H, Giuliano F. Oral drug therapy for erectile dysfunction. Urol Clin North Am 2001;28:321-4.
39. Thandani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002:40:2006-12.
40. Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil citrate for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002;53(suppl 1):61S-5S.
41. Kim S, Narayanan S, Song JC. Tadalafil: an oral selective phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Formulary 2002;37:289-96.
42. Fink HA, MacDonald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002:162:1349-60.
43. Vardenafil (Levitra) for erectile dysfunction. Med Lett Drugs Ther 2003;45:77-8.